Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IVVD
IVVD logo

IVVD Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Invivyd Inc (IVVD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.610
1 Day change
-4.17%
52 Week Range
3.070
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Invivyd Inc (IVVD) is not a strong buy at this time for a beginner investor with a long-term strategy. While the company has shown revenue growth, its declining net income, EPS, and gross margin, combined with hedge fund selling and lack of positive news or catalysts, suggest limited immediate upside potential. The technical indicators and options data also do not provide a compelling case for entry at the current price.

Technical Analysis

The MACD is positive but contracting, RSI is neutral at 64.406, and moving averages are converging, indicating no strong trend. The stock is trading near resistance levels (R1: 1.745) with limited upside potential in the short term.

Options Data

Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
6

Positive Catalysts

  • Revenue increased by 24.51% YoY in Q4 2025, showing some growth potential.

Neutral/Negative Catalysts

  • Net income dropped by 39.98% YoY, EPS fell by 73.33% YoY, and gross margin declined slightly. Hedge funds are selling heavily, and there are no recent positive news or significant insider activity.

Financial Performance

In Q4 2025, revenue increased to $17.2M (up 24.51% YoY), but net income dropped to -$11.07M (down 39.98% YoY). EPS fell to -0.04 (down 73.33% YoY), and gross margin declined slightly to 93.37% (down 1.47% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes available.

Wall Street analysts forecast IVVD stock price to rise
4 Analyst Rating
Wall Street analysts forecast IVVD stock price to rise
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.680
sliders
Low
10
Averages
10
High
10
Current: 1.680
sliders
Low
10
Averages
10
High
10
Boral Capital
D. Boral
Buy
to
Hold
downgrade
AI Analysis
2025-11-25
Reason
Boral Capital
D. Boral
Price Target
AI Analysis
2025-11-25
downgrade
Buy
to
Hold
Reason
D. Boral Capital downgraded Invivyd to Hold from Buy with no price target after the company announced the nomination of its next-generation RSV antibody VBY329 with IND readiness targeted for the second half of 2026 and concurrently strengthened its capital position through a $125M equity offering. With the fundraise anticipated in the firm's prior modeling, the transaction does not alter its valuation framework, but with its previous $2 price target achieved, it now shifts to Hold as the shares more fully reflect pipeline and balance sheet expectations.
H.C. Wainwright
Patrick Trucchio
Buy
maintain
$5 -> $10
2025-10-31
Reason
H.C. Wainwright
Patrick Trucchio
Price Target
$5 -> $10
2025-10-31
maintain
Buy
Reason
H.C. Wainwright analyst Patrick Trucchio raised the firm's price target on Invivyd to $10 from $5 and keeps a Buy rating on the shares after the company unveiled the REVOLUTION clinical program for VYD2311, a vaccine-alternative monoclonal antibody for COVID-19 prevention. The firm views the REVOLUTION launch as a "meaningful inflection point" that strengthens Invivyd's regulatory and commercial narrative.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for IVVD
Unlock Now

People Also Watch